HEARING IMPAIRMENT AND CONGENITAL CMV IN YOUNG CHILDREN

该项目的主要目标是确定流行率， 感音神经性听力进展性和/或延迟性发作的年龄 SNHL最有可能发生在婴儿和幼儿中， 先天性巨细胞病毒（CMV）感染。 我们的项目还将定义 预测CMV感染者SNHL的新生儿期危险因素 无临床明显疾病的婴儿。 我们的第三个目标将定义 巨细胞病毒感染对迟发性听力损失的相对影响 在人口中。 这些目标将通过确定所有 来自大学医院的先天性CMV感染新生儿， 对他们进行一系列测试，以评估他们在不同听力水平下的听力灵敏度。 年龄 此外，随机选择的CMV新生儿对照组 将跟踪和比较来自良好婴儿托儿所的阴性结果， CMV阳性儿童出生时无听力损失。 所有出生的婴儿 目前正在进行病毒学筛查， 先天性巨细胞病毒感染的研究人员提出了这一建议。 3时 每名CMV阳性婴儿在出生后3周、3个月、6个月和12个月时， 由临床听力学家进行完整的听力学评估， 包括听觉脑干诱发反应（ABR）和导抗 每一只耳朵的尺寸 此外，每个孩子都有一个完整的 在18、24和30个月大时进行听力学评估，包括 行为测听评估（视觉强化或游戏 听力测定）和导抗测量以获得纯音阈值、言语 接收阈值和言语辨别分数。 控制 各组将在6岁、12岁和18岁时接受类似的听力评估 月龄。目前有49名先天性CMV感染的新生儿， 第一年入组了178例对照。 约10%的 先天性CMV感染的新生儿有SNHL， 和听力损失的延迟发作记录在前六个月， 生活 对照组中没有一个在出生后第一年患有SNHL。我们 建议将提供更好的知识，流行病学和自然 CMV所致SNHL病史。 这些信息对于规划至关重要 婴幼儿SNHL的早期发现和干预策略 孩子

The primary objective of this project is to determine the prevalence and the ages when progressive and/or delayed onset of sensorineural hearing loss (SNHL) is most likely to occur in infants and young children due to congenital cytomegalovirus (CMV) infection. Our project will also define risk factors in the newborn period that predict SNHL in CMV infected infants without clinically apparent disease. Our third aim will define the relative contribution of CMV infection to delayed onset hearing loss in the population. These aims will be achieved by identifying all newborns with congenital CMV infection from University Hospital and serially testing them to evaluate their hearing sensitivity at various ages. Also, a randomly selected control group of newborns who are CMV negative from the well baby nurseries will be followed and compared to CMV positive children without hearing loss at birth. All infants born at University Hospital are currently screened virologically for congenital CMV infection by the investigators of this proposal. At 3 weeks, 3, 6, and 12 months of age, each CMV positive infant will have a complete audiological evaluation by a clinical audiologist that will include an auditory brainstem evoked response (ABR) and immitance measures for each ear. Also, each child will have a complete audiological evaluation at 18, 24 and 30 months of age that will include behavioral audiometric assessment (visual reinforcement or play audiometry) and immitance measures to obtain pure tone thresholds, speech reception thresholds and speech discrimination scores. The control groups will receive similar audiological evaluations at 6, 12, and 18 months of age. Currently 49 newborns with congenital CMV infection and 178 controls have been enrolled in the first year. About 10% of the newborns with congenital CMV infection have SNHL, with both progression and delayed onset of hearing loss documented in the first six months of life. None of the controls have had SNHL in the first year of life. Our proposal will provide better knowledge of the epidemiology and natural history of SNHL due to CMV. This information is essential for planning early detection and intervention strategies for SNHL in infants and young children.